APA (7th ed.) Citation

ASP, T., JTY, H., SKS, C., J, Q., G, S., F, S., . . . NWS, C. (2025). Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: A comprehensive meta-analysis of number needed to treat, efficacy and safety. Cardiovascular diabetology, 24(1), 285. https://doi.org/10.1186/s12933-025-02840-3

Chicago Style (17th ed.) Citation

ASP, Tang, et al. "Glucagon-like Peptide-1 Receptor Agonist in Myocardial Infarction and Atherosclerotic Cardiovascular Disease Risk Reduction: A Comprehensive Meta-analysis of Number Needed to Treat, Efficacy and Safety." Cardiovascular Diabetology 24, no. 1 (2025): 285. https://doi.org/10.1186/s12933-025-02840-3.

MLA (9th ed.) Citation

ASP, Tang, et al. "Glucagon-like Peptide-1 Receptor Agonist in Myocardial Infarction and Atherosclerotic Cardiovascular Disease Risk Reduction: A Comprehensive Meta-analysis of Number Needed to Treat, Efficacy and Safety." Cardiovascular Diabetology, vol. 24, no. 1, 2025, p. 285, https://doi.org/10.1186/s12933-025-02840-3.